PsyArXiv
December 31, 2025
Sebastian Ehmann, Nikoloz Mosahvili, Angela White et al.
preprint
Psychedelic substances reliably occasion transient self-transcendent states, including mystical-type experiences, which are theorized to support salutogenic psychological change and long-term well-being. Despite growing interest in these phenomena, little is known about how acute self-transcendent states translate into enduring trait-level changes, or whether individual differences such as...
Archives of Psychiatry Research
December 29, 2025
Darko Vlahović, D. Vlahovic
BPL-003 is a novel investigational psychedelic compound being developed for the treatment-resistant depression (TRD). Its active ingredient, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), is a serotonergic psychedelic with preferential agonism at 5-HT1A receptors and rapid pharmacokinetics, allowing for a brief, supervised in-clinic administration. Preclinical studies demonstrate that 5-MeO-DMT...
Psychiatry Research
December 29, 2025
Omer A. Syed, Sean M. Nestor, Muhammad Ishrat Husain et al.
1 citation
Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile within certain clinical populations, little empirical research has explored safety of psychedelic use within real-world samples. Using the World Health Organization (WHO) VigiBase, a comprehensive global pharmacovigilance database with voluntary...
Revista Multidisciplinar do Nordeste Mineiro
December 28, 2025
Marcos Lorran Paranhos Leão, Estácio Amaro Da Silva Júnior
A ayahuasca é uma bebida psicoativa de origem amazônica, tradicionalmente utilizada por povos indígenas e por religiões de matriz brasileira, cuja composição combina plantas ricas em N,N-dimetiltriptamina (DMT) e alcaloides β-carbolínicos. Nas últimas décadas, observa-se crescente interesse científico acerca de seus potenciais efeitos terapêuticos, especialmente no campo da saúde mental, bem...
Current Treatment Options in Psychiatry
December 26, 2025
Manasicha P. Wongpaiboon, Jackson L. Shelton, Eric Delgado Rendon et al.
Purpose A systematic review was conducted to synthesize the efficacy, safety, and tolerability of psychedelics including ketamine, MDMA, ayahuasca, LSD, DMT, ibogaine, and psilocybin in the treatment of PTSD. Recent Findings Among 5,155 studies identified, 42 studies met criteria and were included in our systematic review. Ketamine consistently produced rapid symptom improvement that attenuated...
ACS Medicinal Chemistry Letters
December 16, 2025
Anna C. Renner, Robert B. Kargbo
New inventions introduce complementary advances across neuropsychiatric therapeutics: a blood-based gene-expression diagnostic centered on FOXG1 for objective PTSD detection; benzocyclobutenyl-methylamine modulators that normalize neuronal hyperexcitability; and templated-carrier sublingual 5-MeO-DMT formulations enabling controlled, nonhallucinogenic neuroplasticity. Together, these approaches...
Neuroscience & Biobehavioral Reviews
December 16, 2025
Rivka Vollebregt, A. J. Storm, Paul J. Lucassen et al.
3 citations
Classical psychedelics, like lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and psilocybin, can alter perception, emotion, and cognition, and have shown promise as 're-purposed' treatments for some psychiatric disorders. Recent trials have, e.g., demonstrated rapid and sustained symptom relief in treatment-resistant depression. While promising as a treatment, the...
Zenodo (CERN European Organization for Nuclear Research)
December 15, 2025
preprint
Encounters with seemingly autonomous non-human entities are among the most striking and consistently reported phenomena associated with psychedelic states, particularly those induced by N,N-dimethyltryptamine (DMT). In contemporary discourse, these encounters are frequently described through the archetype of the “machine elf,” a term popularized by ethnobotanist Terence McKenna in the late...
Advanced Neurology
December 4, 2025
Taslim Uddin, Sharmin Akter, Kaustabh Ghosh
Psychedelics are gaining recognition for their effectiveness as modulators of neuroplasticity in the treatment of a range of neuropsychiatric disorders. Psilocybin, lysergic acid diethylamide, N,N-dimethyltryptamine, and ketamine are substances that mainly affect the serotonergic and glutamatergic systems. They induce rapid synaptogenesis, dendritic remodeling, and changes in functional...
Journal of Magnetic Resonance Imaging
December 1, 2025
Lucas Rego Ramos, Orlando Fernandes, Tiago Arruda Sanchez
1 citation
Ayahuasca is an Amazonian psychedelic brew that contains dimethyltryptamine (DMT) and beta carbolines. Prolonged use has shown changes in cognitive-behavioral tasks, and in humans, there is evidence of changes in cortical thickness and an increase in neuroplasticity factors that could lead to modifications in functional neural circuits. To investigate the long-term effects of Ayahuasca usage...